A 64-year-old man with a history of advanced squamous cell carcinoma of the lung is brough… — USMLE Step 3

A $64$ -year-old man with a history of advanced squamous cell carcinoma of the lung is brought to the emergency department by his family due to progressive lethargy, confusion, and generalized weakness over the past $3$ days. He has also been experiencing severe nausea, vomiting, and polyuria. Vital signs show a temperature of $37.2^\circ\text{C}$ ( $99.0^\circ\text{F}$ ), heart rate of $112/\text{min}$ , blood pressure of $88/58\text{ mmHg}$ , and respiratory rate of $16/\text{min}$ . Physical examination reveals dry mucous membranes, flat jugular veins, and delayed capillary refill. He is disoriented to time and place. Laboratory results are as follows:

Serum calcium: $14.8\text{ mg/dL}$
Serum albumin: $3.5\text{ g/dL}$
Blood urea nitrogen (BUN): $42\text{ mg/dL}$
Serum creatinine: $1.4\text{ mg/dL}$ (baseline $0.9\text{ mg/dL}$ )

Electrocardiogram shows a shortened QT interval. Which of the following pharmacologic interventions are indicated in the initial management of this patient's acute metabolic derangement? (Select all that apply)

Intravenous $0.9\%$ sodium chlorideAnswer
Subcutaneous calcitoninAnswer
Intravenous zoledronic acidAnswer
D
Intravenous furosemide
E
Intravenous hydrocortisone

Answer

The indicated interventions are intravenous 0.9% sodium chloride, subcutaneous calcitonin, and intravenous zoledronic acid.

The standard of care for severe hypercalcemia of malignancy (calcium > 14.0 mg/dL) requires a simultaneous three-tiered approach. First, aggressive intravenous hydration with 0.9% sodium chloride is essential to reverse volume depletion, improve the glomerular filtration rate, and enhance renal calcium excretion. Second, calcitonin is given because it rapidly inhibits osteoclastic bone resorption and promotes renal calcium excretion, usually lowering calcium levels within 4 to 6 hours. Third, an intravenous bisphosphonate (such as zoledronic acid or pamidronate) is administered to provide a sustained reduction in calcium levels. Because bisphosphonates take 48 to 72 hours to achieve their full clinical effect, they must be given early alongside the faster-acting therapies.

Step-by-Step Solution

Identify the primary clinical derangement.

The patient has severe hypercalcemia of malignancy (calcium > 14.0 mg/dL) presenting with altered mental status and profound volume depletion (hypotension, tachycardia, AKI).

Severe symptomatic hypercalcemia requires immediate, multipronged pharmacologic intervention.

Select the intervention for immediate hemodynamic stabilization and renal clearance.

Administer aggressive intravenous isotonic fluid (0.9% sodium chloride).

Hypercalcemia induces nephrogenic diabetes insipidus; the resulting hypovolemia decreases the glomerular filtration rate, exacerbating calcium retention. Fluids restore GFR and promote calciuresis.

Select a fast-acting targeted pharmacologic therapy.

Administer calcitonin.

Calcitonin acts within 4 to 6 hours to inhibit osteoclast activity, rapidly lowering serum calcium levels.

Select a definitive long-acting pharmacologic therapy.

Administer an intravenous bisphosphonate (zoledronic acid).

Bisphosphonates are highly effective at inhibiting osteoclastic bone resorption but take 2 to 3 days to peak, so they must be administered concurrently with rapid-acting therapies.

Key Concept

Acute multidrug management of severe hypercalcemia of malignancy

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic